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Abstract 
 
Background: The effectiveness of ABC has been traditionally measured as 
the reduction in internal margin (IM) within the planning target volume (PTV). 
Not to overestimate the benefit of ABC, the effect of patient movement during 
treatment also needs to be taken into account. We determined the IM and set-
up error with ABC and the effect on physical lung parameters compared to 
standard margins used with free breathing. We also assessed interfraction 
oesophageal movement to determine a planning organ at risk volume (PRV).  
 
 
Materials and Methods: Two sequential studies were performed using ABC 
in NSCLC patients suitable for radical radiotherapy (RT). Twelve out of 
fourteen patients in Study 1had tumours visible fluoroscopically and  had 
intrafraction tumour movement assessed with and without ABC. Sixteen 
patients were recruited to Study 2 and had interfraction tumour movement 
measured using ABC in a moderate deep inspiration breath-hold, of these 7 
patients also had interfraction oesophageal movement recorded. Interfraction 
movement was assessed by CT scan prior to and in the middle and final week 
of RT. Displacement of the tumour centre of mass and oesophageal borders 
relative to the first scan provided a measure of movement. Set-up error was 
measured in 9 patients treated with an in-house lung board adapted for the 
ABC device. Combining movement and set-up errors determined PTV and 
PRV margins with ABC. The effect of ABC on mean lung dose (MLD), lung 
V20 and V13 and was calculated. 
 
3 
 
 
Results: ABC in a moderate deep inspiration breath hold was tolerated in 25 
out of 30 patients (83%) in Study 1 and 2. The random contribution of periodic 
tumour motion was reduced by 90% in the y direction with ABC compared to 
free-breathing. The magnitude of motion reduction was less in the x and z 
direction.  Combining the systematic and random set-up error in quadrature 
with the systematic and random intrafraction and interfraction tumour 
variations with ABC results in a PTV margin of 8.0 mm in the x direction, 11.4 
mm in the y direction and 9.4 mm in the z direction. There was a relative 
mean reduction in MLD, lung V20 and V13 of 25%, 21% and 18% with the ABC 
PTV compared to a free-breathing PTV. Oesophageal movement combined 
with set-up error resulted in an isotropic PRV of 5.1 mm. 
 
Conclusions: The reduction in PTV size with ABC resulted in a 18-25% 
relative reduction in physical lung parameters. PTV margin reduction has the 
potential to spare normal lung and allow dose-escalation if coupled with 
image-guided RT. The oesophageal PRV needs to be considered when 
irradiating central disease and is of increasing importance with altered RT 
fractionation and concomitant chemoradiation schedules. Further reductions 
in PTV and PRV may be possible if patient set-up error was minimised 
confirming that attention to patient immobilisation is as important as attempts 
to control tumour motion. 
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Introduction 
Radical radiotherapy (RT) with or without chemotherapy is the primary 
treatment for patients with locally advanced unresectable or medically 
inoperable non-small cell lung cancer (NSCLC).  Increasing conventional RT 
dose from 40 - 60 Gy and dose intensification with continuous 
hyperfractionated accelerated radiotherapy (CHART) result in improved local 
control and survival in patients treated with radical RT1, 2. Increasing dose 
beyond the tolerance limits of normal lung, however, leads to an increased 
risk of radiation-induced pulmonary toxicity 3-5.  The addition of sequential or 
concomitant cisplatin-based chemotherapy to RT improves survival by 4-5% 
at 2 years. Concomitant treatment, however, is associated with an increased 
risk of radiation-induced oesophageal toxicity6-11.  
 
The aim of modern RT is to increase dose to the tumour without additional 
normal tissue toxicity by minimising the dose to normal tissues.  When applied 
to radical RT for NSCLC this principally means avoiding high dose radiation to 
normal lung.  One of the main challenges in reducing normal lung irradiation is 
respiration induced tumour movement. Conventional NSCLC RT deals with 
the problem of external patient movement and internal tumour movement by 
employing wide margins around the clinical target volume (CTV) producing a 
large planning target volume (PTV)12. The CTV-PTV margin encompasses an 
internal margin (IM) which covers variations in tumour movement and a set-up 
error margin (SM) for external patient movement13. The IM can include a large 
volume of normal lung limiting the dose that can be delivered to the tumour.   
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Techniques that reduce both patient and tumour movement facilitate a 
reduction in the PTV, thereby reducing the volume of normal lung irradiated 
and potentially allow for dose escalation. Two strategies to compensate for 
tumour movement have evolved. The first aims to reduce internal respiration 
induced movement by maintaining a breath-hold, either actively or passively 
14-17
. The second allows the patient to breathe freely with RT delivery either 
synchronised during a pre-defined phase of the respiratory cycle or 
continuously delivered while tracking the tumour 18-20.   
 
This study addresses the effect of a breath-holding technique using an Active 
Breathing Control (ABC) device (The William Beaumont Hospital, USA). While 
the majority of studies assessing the value of ABC concentrate on the 
magnitude of benefit in isolation, we evaluated it in the context of the 
uncertainty of patient movement during a course of RT. We also assessed 
oesophageal movement with ABC to determine a planning organ at risk 
volume (PRV) to explore strategies to reduce oesophageal toxicity during 
concomitant chemo-radiation. This study provides the basis for appropriate 
margins for lung tumours and organs at risk (OAR) using ABC and estimates 
the effect on physical lung parameters.   
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Patients and methods 
The studies were approved by the institutional committee for clinical research 
and the local ethics committee. Eligible patients gave written informed 
consent.  
 
Patient characteristics 
Between February 2002 and October 2004, 30 patients were recruited to two 
consecutive studies conducted to assess intrafraction and interfraction tumour 
and oesophageal movement with ABC. Eligible patients had histologically 
proven NSCLC and were fit enough for radical RT. 
 
14 patients recruited to Study 1 to assess intrafraction tumour movement with 
ABC had a mean age of 72 years (range 46 - 82 years). Patient and tumour 
characteristics are shown in Table 1. Two patients were excluded from the 
analysis as the tumour was poorly visualised fluoroscopically (Patients 3 and 
4). Twelve completed radical RT and two received a palliative schedule.  
 
16 patients recruited to Study 2 to assess interfraction tumour movement had 
a mean age of 70 years (range 52 - 83 years).  Patient and tumour 
characteristics are shown in Table 2. Two patients progressed during 
treatment (Patients 3 and 5) and two did not tolerate the ABC device and 
were excluded from further analysis (Patients 8 and 15). In 7 out of the 
remaining 12 patients, interfraction oesophageal movement was assessed. 
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The ABC device  
The ABC device consisted of a mouthpiece connected to a transducer turbine 
air flow meter coupled to a balloon valve14. A nose clip was used to ensure 
breathing was only through the mouthpiece. The resting tidal volume and 
maximum inspiratory volume (MIV) were recorded. The valve was closed at 
moderate deep inspiration breath hold (mDIBH) set at 75% of MIV. In the 
training phase mDIBH was initially held for 5 seconds and then increased by 5 
second increments up to a maximum of 30 seconds depending on individual 
tolerance. The patients were coached during this training phase using audio 
prompting. Normal breathing could be resumed either by operating a hand-
held switch to open the balloon valve or by releasing the mouthpiece. The 
breathing trace was reset to zero baseline at the end of exhalation.  
 
Intrafraction tumour movement 
Patients were positioned supine on the simulator couch as for treatment with 
the arms raised above the head (Philips Oncology Systems simulator SLS 
23). Images were obtained using a digital simulation system (Oncentra SIM 
1.3, MDS Nordion). The tumour was visualised fluoroscopically. We were able 
to measure the maximal tumour movement rather than the detailed spatial 
density distribution. This gave the worst-case scenario for the margins without 
breathing control. To obtain an estimate of the effects of the spatial probability 
distribution, an estimated SD of 1/3 of the peak to peak amplitude (based on 
idealised distributions present in the literature) was also calculated. See 
Wolthaus IJROBP 2006; van Herk Semin Radiat Oncol 2004, Evans 2006 
{need to put in green journal format} Independent field wires were used to 
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define the full extent of left-right (x) and superior-inferior (y) movement on the 
anterior-posterior view and anterior-posterior (z) movement on the lateral 
view. Maximal tumour movement was measured during free breathing and 
with ABC in mDIBH. Breath-holds were repeated four times. A change in 
tumour position between breath-holds with respect to the field wires was 
corrected for with couch movement. The magnitude of couch movement gave 
an indication of reproducibility of tumour position between breath-holds. This 
was confirmed by comparing the images in Oncentra SIM.  
 
Interfraction organ movement with ABC 
Patients in Study 2 had a RT planning CT scan (ABC1) of the whole thorax in 
the treatment position at 3 mm slice intervals. The duration of the breath hold 
necessary for the CT scan related to the length of the thorax and was up to 20 
seconds. Two further CT scans using ABC were carried out in the middle 
(ABC2) and final week (ABC3) of a 6 ½ week course of radiotherapy. The 
same mDIBH gate volume was used for ABC2 and ABC3 as for ABC1.  
 
Co-registration of the CT scans 
The ABC2 and ABC3 CT scans were co-registered to the ABC1 CT scan by 
matching the vertebral bodies at the level of the tumour. The gross tumour 
volume (GTV) was defined as the primary tumour mass and lymph nodes ≥ 1 
cm in diameter. OAR contoured included both lungs as a single organ 
(excluding the GTV), the spinal cord and the oesophagus from the thoracic 
inlet to the gastro-oesophageal junction. The GTV and OARs were contoured 
by the same physician on all scans.  
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Assessment of interfraction tumour and oesophageal movement 
The centre of mass (COM) of the GTV was determined by the treatment 
planning system using a spherical autoplace function. The standard deviation 
(SD) of displacement of the GTV COM on ABC2 and ABC 3 relative to ABC1 
provided a measure of movement of the GTV. The oesophageal position was 
determined by the relation of its anterior, posterior, left lateral and right lateral 
borders relative to the most anterior aspect of the vertebral body in the midline 
(Figure 1).  The oesophageal position was recorded at 4 cm intervals along 
the length of the oesophagus in relation to a fixed bony reference point 
around the level of the carina. The carina was defined as the point where the 
trachea bifurcates and two separate bronchi are seen adjacent to each other. 
The bony reference point (position 3) was defined in relation to the carina at 
the point where the superior border of the ribs inserted onto the vertebral 
body. Oesophageal border measurements were taken from the reference 
position 3 up to 8 cm superiorly at positions 1 and 2 and 12 cm inferiorly at 
positions 4, 5 and 6 (Figure 2). The SD of displacement of the oesophageal 
borders at levels 1 to 6 on ABC2 and ABC3 relative to ABC1 provided a 
measure of movement of the oesophagus.  
 
Patient set-up 
Patients using the ABC device were immobilised with the arms raised above 
the head on a lung board designed to support the elbows. Set-up 
measurements were taken in the 9 patients (Patients 3, 8, 10, 11, 12, 13, 14, 
15 and 16) treated on the lung board. Treatment portal images generated 
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from an electronic portal imaging (EPI) device (Elekta iview GT) were 
compared to a reference image (digitally reconstructed radiograph) and 
matched to bony anatomy. Orthogonal images were taken on days 1, 2 and 3 
and the systematic set-up error was calculated and corrected for off-line. 
Thereafter weekly images were taken and assessed using a tolerance of 5 
mm. The set-up error in the y direction was measured on both the anterior 
and lateral EPI with only the anterior field measurements used in this study. 
The systematic  set-up error (Σ) for the group was defined as the SD of the 
distribution of the average set-up displacements for each patient and the 
random error (σ) was the SD of the individual patients set-up displacements 
averaged over all the patients in the group21.  
 
PTV and PRV calculations 
The CTV-PTV margin was calculated using 2.5Σ + 0.7σ, where Σ is the total 
systematic error including set-up and CTV movement and σ is the 
corresponding total random error22. For the purposes of this study the 
localised GTV was equivalent to the CTV. The systematic variation of the 
GTV COM with ABC was defined as the SD of the mean tumour movement 
on ABC2 and ABC3 relative to ABC1 for each patient. The random variation 
with ABC was defined as the average of the SD for movement of the tumour 
in each patient. The systematic and random contributions to the margin were 
combined in quadrature with the systematic and random set-up error in the x, 
y and z direction to produce a generic non-uniform PTV margin using ABC. 
For the purposes of this study, variations in intra-observer tumour delineation 
were not determined. 
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Irradiation of the oesophagus is of importance in relation to the high dose area 
in proximity to the PTV.  The OAR to PRV margin was calculated using 1.3Σ + 
0.5σ, where Σ is the systematic set-up error and systematic movement of the 
oesophagus and σ is the random set-up error and random movement of the 
oesophagus23. The systematic variation of the oesophagus with ABC was 
defined as the SD of the mean movement of the oesophagus on ABC2 and 
ABC3 relative to ABC1. The random variation was defined as the average of 
the SD for movement of the oesophagus in each patient. The systematic and 
random contributions to the margin were combined in quadrature with the 
systematic and random set-up error in the x and z direction and then 
averaged to produce a generic uniform PRV margin using ABC.  
 
Effect of target volume changes with ABC on physical lung parameters  
Three treatment plans were generated in 10 patients from Study 2 using the 
ABC1 CT dataset. All plans were generated using the same beam 
arrangement, weighting, wedges and dose prescription. In the first plan the 
GTV-PTV margin was 15 mm in the y direction and 10 mm in the x and z 
direction as is the standard practice in our institution (standard PTV). In the 
second plan an isotropic 15 mm margin was applied, except in the y direction 
in patients 4 and 9, who had tumours near the diaphragm where a 20 mm 
margin was used (free-breathing PTV). These were compared to a third plan 
which employed the GTV-PTV margin defined by tumour movement with ABC 
as described above (ABC PTV). The effect of the change in PTV size with 
ABC compared to the standard and free-breathing PTV was assessed by 
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comparing the mean lung dose (MLD), volume of lung irradiated to ≥ 20 Gy 
(V20 ) and the volume of lung irradiated to ≥ 13 Gy (V13). 
 
Statistical considerations 
To assess the tolerability of ABC in lung cancer patients for treatment, we 
anticipated that 80% of patients would be able to manage a mDIBH of 20 
seconds or more. A success rate of < 50% was considered too low for the 
introduction of the device into routine clinical practice. A minimum of 14 
patients were required to exclude an acceptability of < 50%. The quantile-
quantile plot method was used to confirm the normal assumptions in the 
intrafraction tumour movement data and Student’s t-test used to compare 
datasets. We determined the distribution of tumour and oesophageal 
movement using the Kolmogorov-Smirnov test of normality with Lilliefors 
Significance Correction. Where the distribution was Gaussian, the SD of 
tumour and oesophageal displacement between ABC2 and ABC3 relative to 
ABC1 provides a measure of interfraction movement. The effect of PTV size 
on lung parameters was compared using the Wilcoxon matched paired t-test. 
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Results 
Breath-hold tolerance 
Eleven of 14 patients (79%) in study 1, managed breath-holds of 20 seconds 
or more and the mean number of mDIBHs were 11. The mean breath-hold 
time was 19 + 5 seconds (+ 1 SD). Three patients managed breath-holds of 
less than 20 seconds and of these, two managed 10 seconds only.  
 
Twelve of 16 patients (75%) in study 2 had 3 sequential CT scans with ABC 
during the course of RT and were eligible for further analysis. Two did not 
tolerate the ABC device and two had disease progression during treatment 
and were withdrawn from the study.  The mean breath-hold time was 23 + 5 
seconds (+ 1 SD) for ABC1, 22 + 6 seconds for ABC2 and 20 + 6 seconds for 
ABC3.  
 
Intrafraction movement of the GTV with ABC  
Two patients were excluded from the analysis as the tumour was poorly 
visualised fluoroscopically (Patients 3 and 4). The mean, SD,and range of 
intrafraction tumour movement with free- breathing and ABC are shown in 
Table 3 along with the SD of one-third of the peak-to-peak amplitude. The 
random contribution of periodic tumour motion was reduced by 90% in the y 
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direction with the use of ABC. The magnitude of motion reduction was less in 
the x and z direction. Only one patient required couch correction of 20 mm to 
correct for tumour displacement from the original breath-hold position. 
Subsequent breath-holds for this patient required no correction and on review 
of the digital images it was found that the correction was required due to 
patient movement. 
 
Interfraction movement of the GTV with ABC 
Overall interfraction tumour variation in the x, y and z direction had a 
Gaussian (p > 0.05) distribution (p = 0.200; p = 0.193; p = 0.058 respectively) 
.The mean and SD of displacement of the GTV COM on ABC2 and ABC3 
relative to ABC1 are shown in Table 4.  The systematic and random variations 
of the tumour with ABC is shown in Table 5. Individual values of displacement 
of the GTV COM in the superior-inferior direction between ABC3 and ABC1 
are shown in Figure 3. The shift in tumour position was most marked in 
patients 2 and 9 in the final week of RT due to tumour shrinkage and 
resolution of distal collapse and consolidation. 
 
Interfraction oesophageal displacement 
A total of 504 oesophageal measurements were analysed in 7 patients. The 
range of displacement was -6.2 mm to 9.0 mm in anterior, -4.3 mm to 7.6 mm 
in posterior, -10.9 mm to 7.3 mm in left lateral and -5.6 mm to 11.6 mm in right 
lateral directions. The extent of oesophageal movement varied along the 
length of the oesophagus. Movement was more marked at the level of the 
bifurcation of the trachea (range 7.7 mm to 16.1 mm) and the gastro-
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oesophageal junction (range 9.4 mm to 14.7 mm) and less marked at the 
thoracic inlet (range 4.4 mm to 6.9 mm). The mean and SD of oesophageal 
movement on ABC2 and ABC3 relative to ABC1 is shown in Table 6 along 
with the systematic and random variation of the oesophagus in the anterior, 
posterior, left lateral and right lateral direction averaged over all levels.   
 
Set-up error 
A total of 156 EPIs were assessed for set-up error in 9 patients treated on the 
lung board. Table 7 shows the average and SD for set-up error in each 
patient. The systematic and random set-up error in the x direction was 1.5 mm 
and 2.4 mm, in the y direction was 1.9 mm and 2.9 mm and in the z direction 
was 1.9 mm and 2.2 mm respectively. This is representative of set-up error 
using the lung board in our department. 
 
PTV and PRV calculations 
Combining the systematic and random set-up error in quadrature with the 
systematic and random intrafraction and interfraction tumour variations with 
ABC results in a PTV margin of 8.0 mm in the x direction, 11.4 mm in the y 
direction and 9.4 mm in the z direction (Table 8). Assuming no change in 
oesophageal position during treatment, combining the systematic and random 
set-up error in quadrature with the systematic and random oesophageal 
variation with ABC results in a PRV margin of 4.5 mm anteriorly, 4.8 mm 
posteriorly, 4.2 mm in the right lateral direction and 6.9 mm in the left lateral 
direction which can be averaged resulting in a 5.1 mm uniform margin (Table 
9 and 10). 
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Target volume planning study  
The reduction in PTV size with ABC compared to the standard and free-
breathing PTV results in a reduction in all the physical lung parameters 
measured. The mean (+ 1 SD) MLD, V20 and V13 for all PTVs are shown in 
Table 11. The relative mean reduction in lung parameters between the 
standard PTV and the ABC PTV was 10 % for MLD, 6 % for V20 and 8 % for 
V13 (all p values = 0.002) The relative mean reduction in lung parameters 
between the larger free-breathing PTV and the ABC PTV was 25% for MLD (p 
< 0.0001), 21% for V20 (p = 0.0002) and 18% for V13 (p < 0.0001). 
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Discussion 
Although patients with NSCLC are elderly and have frequent lung co-
morbidity the majority of those suitable for radical RT (83%) are able to 
tolerate ABC. They also retain their ability to maintain a mDIBH throughout a 
course of treatment. ABC significantly reduces intrafraction tumour movement 
but does not guarantee a fixed tumour position throughout treatment. Tumour 
shrinkage and resolution of distal collapse and consolidation may be 
responsible for a shift in tumour position. The impact of ABC on the GTV-PTV 
margin is less than would be expected judging by the reduction in tumour 
motion with a breath-hold due to the additional effect of patient movement and 
set-up error. Nevertheless, ABC results in a mean relative reduction in lung 
DVH parameters determining risk of pneumonitis by up to 25% with the 
potential for safe dose escalation. Oesophageal movement may be of 
relevance when optimising RT plans to reduce oesophageal toxicity in 
combined modality treatments. 
 
The determination of intrafraction tumour movement relied on fluoroscopic 
orthogonal information and was therefore potentially less accurate than 
assessment by respiratory correlated CT scanning. Studies of intrafraction 
tumour motion using fluoroscopy at simulation have shown reasonable 
correlation with that observed during treatment suggesting that it is a valid 
method for assessing motion on a coarse scale [Erridge S 2003 R+O]. Our 
results on intrafraction tumour motion with free-breathing are similar to 
reported 3-D tumour motion assessed using fiducial markers inserted near 
lung tumours24. The average amplitude of motion is greatest in the y direction 
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and was reported to be 12.0 mm + 2.0 mm (+ 1 SD) for lower lobe tumours 
not attached to rigid structures24. This compares with intrafraction motion in 
the y direction in this study of 8.0 mm + 6.8 mm (+ 1 SD) where only two 
patients had lower lobe tumours near the diaphragm. Intrafraction tumour 
movement in the y direction, which is dependent on diaphragmatic and chest 
wall motion, was largely eliminated with ABC. Movement of the tumour in the 
x and z direction was reduced but not eliminated with ABC. This is probably 
due to pulsatile movement transmitted from the heart and aorta and concurs 
with reported displacement of 1.0 to 4.0 mm greatest in the x direction24.  
 
Interfraction tumour movement was assessed by CT imaging of the thorax in 
mDIBH and was restricted to 3 scans to avoid excess radiation exposure. 
Interfraction tumour movement with ABC supports reported results of mean 
tumour motion of 0.3 mm + 1.8 mm (+ 1 SD) in the x, 1.1 mm + 3.5 mm in the 
y and 1.2 mm + 2.3 mm in the z direction where the suggested margin 
necessary to account for movement with 95% confidence would be twice the 
SD15. ABC in mDIBH with standard GTV-PTV margins can result in a median 
reduction in lung V20 of 6.4% and reduces maximum spinal cord dose in up to 
80% of patients suitable for radical RT16. This is due to lung expansion 
resulting in movement of the lung from areas of high dose irradiation and 
movement of the tumour away from the spinal cord. The impact of ABC on 
tumour motion cannot be considered in isolation and has to take into account 
daily set-up error during treatment. Combining set-up inaccuracies with 
tumour motion provides an objective and realistic assessment of the potential 
benefit of ABC for daily treatment. 
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Reducing tumour motion with a breath-hold, however, does not guarantee a 
lack of shift in tumour position during a course of fractionated RT. Intrafraction 
tumour motion with ABC reported in 8 patients treated with 7 weeks of RT 
was 0.9 mm to 5.9 mm, 2 of these 8 patients had lung volume changes of > 
300 cm3 and tumour displacements of > 10 mm thought to be due to adjacent 
lung atelectasis17. This is in keeping with our observation in 2 patients who 
had a shift in tumour position in the superior-inferior direction of up to 7.7 mm 
in the final week of RT due to tumour shrinkage and resolution of distal 
collapse and consolidation. This can have significant implications on the 
targeting of highly conformal RT during conventionally fractionated treatment 
necessitating the need for appropriate monitoring and adjustment. Patients 
with lung volume loss associated with the tumour should either not be treated 
with ABC or be treated in the context of an image-guided RT protocol to 
prevent geographic miss. 
 
There is increasing evidence for improved outcomes with concomitant 
chemoradiation and altered fractionation RT schedules [Rowell NP, 
chemoradiotherapy in NSCLC Cochrane review 2005; Rakovitch E, Red J 
2004; Auperin A 2006 Ann Oncol; Saunders Lancet 1997]. Both these 
treatment techniques result in an increased risk of radiation-induced acute 
and late oesophageal toxicity affecting not only patient’s quality of life but 
potentially causing interruptions during RT and compromising treatment [Cox 
JD 1995 IJROBP Interruptions of high-dose RT]. In order to develop 
strategies to reduce oesophageal toxicity when there is mediastinal disease 
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an assessment of interfraction oesophageal movement was felt necessary to 
avoid high dose irradiation of this structure.  
 
The relative mean reduction in physical lung parameters that determine lung 
toxicity was 6-10% with ABC compared to our standard GTV-PTV margin and 
18-25% compared to the free-breathing GTV-PTV margin. The magnitude of 
benefit of ABC on lung parameters may have been underestimated in this 
study due to the potential differences in tumour size and lung volume seen 
when patients are CT scanned during a breath-hold compared to CT scanning 
during tidal free-breathing15, 16. Acquiring a CT scan during a breath-hold 
reduces imaging motion artefact due to respiration resulting in a smaller more 
defined GTV15, 16. It has also been shown that increasing the lung volume with 
a deep inspiration breath-hold alone results in a median reduction in the V20 of 
almost 2% compared to tidal breathing lung volumes25. In this study, the 
standard and free-breathing GTV-PTV margin was applied to patients 
scanned in breath-hold. If the patients had been scanned during tidal 
breathing the effect may have been an increase in GTV size, due to motion 
artefact together with a reduction in total lung volume. Using a constant GTV-
PTV margin, an increase in GTV size and reduction in lung volume would 
result in an increase in the relative volume of lung irradiated to high doses. 
The real benefit therefore, of planning treatment with ABC in breath-hold may 
be greater than that reported here if the standard GTV-PTV margin had been 
applied to patients scanned while free-breathing. 
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Conclusion 
These studies demonstrate that ABC is tolerated in a large proportion of lung 
cancer patients and reduces intrafraction and interfraction tumour motion in 
the absence of lung atelectasis. Incorporation of ABC into 3-D conformal 3-
field coplanar treatment would require patients to maintain a 20 second 
breath-hold up to 6 times daily for treatment. There was no deterioration in 
patients’ ability to maintain a breath-hold in the final week of RT, but requiring 
them to do this repeatedly on a daily basis has not been assessed. ABC 
cannot be considered in isolation and should be coupled with attempts to 
minimise set-up errors to facilitate PTV margin reduction and dose escalation. 
Oesophageal movement with ABC can be incorporated into a PRV to explore 
the possibility of using highly conformal RT to avoid the oesophagus during 
concomitant chemo-radiation schedules. 
 
The tolerability and reproducibility of ABC and impact on treatment time need 
to be assessed during daily treatment of NSCLC before routine 
implementation of reduced PTV margins and potential dose escalation. 
 
Acknowledgements 
This work was supported in part by the Royal Marsden NHS Foundation Trust 
and Cancer Research UK.  The Royal Marsden NHS Foundation Trust 
receives a proportion of its funding from the NHS Executive; the views 
expressed are those of the authors and not necessarily those of the NHS 
Executive.   
22 
 
 
Tables and Figures 
Table 1. Patient and tumour characteristics in Group 1 
 
Patient PS Smoker FEV1  TNM Stage Tumour site 
No. 
 
1  0 Yes  <1  T2N1M0 RUL central 
2  1 Ex  <1  T2N2M0 RUL peripheral 
3  0 Yes  0.9  T1N0M0 RUL peripheral 
4  0 No  <1  T1N0M0 LLL central 
5  1 Ex  NA  T2N0M0 LLL peripheral 
6  1 Yes  NA  T4N2M0 RUL central 
7  1 Yes  1.4  T2N0M0 LUL central 
8  1  Ex  1.4  T2N2M0 RLL peripheral 
9  0 No  1.3  T1N0M0 RUL peripheral 
10  1 Yes  1.2  T3N3M0 RUL central 
11  0 Ex  NA  T3N1M0 LUL central 
12  1 Ex  NA  T3N0M0 RUL central 
13  1 Yes  0.7  T2N0M0 LUL peripheral 
14  1 No  NA  T3N1M0 LULcentral 
 
Table key: No. = number; PS = ECOG performance status; FEV1 = forced 
expiratory volume in 1 second; Ex = ex-smoker > 5 years; NA = data not 
available; LUL = left upper lobe; RUL = right upper lobe; RML = right middle 
lobe; LLL = left lower lobe; RLL =  right lower lobe 
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Table 2. Patient and tumour characteristics in Group 2 
 
Patient PS Smoker FEV1  TNM Stage Tumour site 
No. 
 
1  1 Ex  1.6  T2N0M0 LUL peripheral 
2  1 No  1.3  T2N0M0 RUL central 
3  1 Ex  1.3  T4N2M0 RUL central 
4  0 Yes  1.3  T2N0M0 RML peripheral 
5  1 Yes  1.8  T3N0M0 RLL peripheral 
6  0 Yes  NA  T3N2M0 LUL central 
7  1 Ex  1.7  T2N2M0 RML central 
8  1 Yes  NA  T2N2M0 RLL central 
9  1 Yes  0.7  T1N0M0 RLL peripheral 
10  1 No  1.9  T4N0M0 LLL central 
11  0 Yes  1.9  TxN2M0 Mediastinal 
12   1 Yes  1.5  T2N0M0 LUL central 
13  1 Yes  NA  T2N1M0 RUL peripheral 
14  0 Ex  1.2  T1N0M0 RML central 
15  1 Yes  1.6  T1N0M0 LUL peripheral 
16  1 Yes  NA  TxN2M0 Mediastinal 
 
 
Table key: No. = number; PS = ECOG performance status; FEV1 = forced 
expiratory volume in 1 second; Ex = ex-smoker > 5 years; NA = data not 
24 
 
 
available; LUL = left upper lobe; RUL = right upper lobe; RML = right middle 
lobe; LLL = left lower lobe; RLL =  right lower lobe 
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Figure 1. Method for obtaining oesophageal measurements, with the 
oesophagus outlined in purple  
 
 
 
 
 
 
 
 
 
 
Figure 2. CT scan of the thorax with PTV in purple and oesophagus in yellow.  
-------- position 1 
         -------- position 2 
         -------- position 3 
-------- position 4 
-------- position 5 
-------- position 6 
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Table 3. Intrafraction tumour movement with free-breathing and ABC in the 12 
patients in Study 1. 
 
  Free-breathing ABC   Reduction with ABC 
  x y z x y z x y z 
 
mm 
Mean  4.2 8.0 5.1 0.6 0.3 0.6 3.6 7.7 4.5 
SD   2.6 6.8 2.8 1.2 0.5 0.7 
Range  0-9 0-21 0-9 0-3 0-1 0-2 0-6 0-21 0-9 
SD max/3 0.9 2.3 0.9 0.4 0.2 0.2 
 
Table key: x = right-left direction; y = superior-inferior direction; z = anterior-
posterior direction; SD = + 1 standard deviation; SD max/3 = standard 
deviation of one-third of the peak-to-peak amplitude for each tumour 
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Table 4. Interfraction tumour movement with ABC measured as the position of 
GTV COM on ABC2 and ABC3 relative to ABC1 in the 12 patients in Study 2 
 
 
   Mean displacement (SD) in mm 
 
ABC scan  x  y  z 
 
GTV ABC2-1 0.3 (2.1) 1.1 (2.1) -0.2 (2.4) 
GTV ABC3-1 -0.6 (1.2) 0.7 (3.9) -0.7 (2.2) 
 
Table key: x = right-left direction; y = superior-inferior direction;  
z = anterior-posterior direction; SD = + 1 standard deviation 
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Table 5. Systematic and random movement of the GTV COM with ABC in the 
12 patients in Study 2 
 
   Direction of movement of the GTV COM (mm) 
   x   y   z 
 
Systematic  1.5   2.8   2.0 
Random  1.7   3.0   2.3 
 
Table key: x = right-left direction; y = superior-inferior direction; z = anterior-
posterior direction 
 
 
Figure 3. Displacement of the GTV COM in the y direction between ABC3 and 
ABC1 (in cm) 
Difference in GTV COM in the superior-inferior (y) 
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Table 6. Interfraction, systematic and random movement of the oesophagus 
relative to ABC1 in 7 patients in Study 2 
 
  Direction of movement: mean (SD) in mm 
 
ABC scan Anterior Posterior Left Lateral Right Lateral 
 
ABC2-1 0.1 (1.8) 1.4 (1.7) -1.2 (1.0) 1.0 (1.7) 
ABC3-1 0.9 (2.2) 0.5 (1.3) -0.9 (1.3) 0.4 (2.0) 
 
Σ  1.8  1.3  1.1  1.3 
σ  1.8  2.0  2.7  2.1 
 
Table key: SD = + 1 standard deviation; Σ = systematic movement; σ = 
random movement 
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Table 7. Patient set-up accuracy with the lung board in Study 2 
 
Pt. No. No. of  Mean disp. Mean disp. Mean disp. 
  meas.  x in mm y in mm z in mm 
    (SD)  (SD)  (SD) 
 
3  3  -2.8 (1.1) 0.0 (2.8) 0.5 (3.7) 
8  14  0.1 (2.7) 1.1 (3.4) 2.5 (3.4) 
10  8  0.5 (2.2) 2.7 (1.3) 0.2 (1.9) 
11  14  0.1 (3.4) -2.6 (4.5) -3.7 (2.8) 
12  7  -0.5 (1.3) 3.3 (1.5) 2.1 (1.4) 
13  8  -1.8 (2.7) 2.3 (2.9) -1.2 (0.9) 
14  9  -1.7 (3.0) 0.6 (3.5) 1.2 (2.9) 
15  9  -2.3 (3.7) 3.0 (4.9) 1.2 (1.4) 
16  6  1.9 (1.9) -0.1 (0.9) -0.6 (1.3) 
 
Table key: Pt. No. = patient number; No. of meas. = number of 
measurements; x = right-left direction; y = superior-inferior direction; z = 
anterior-posterior direction; SD = + 1 standard deviation 
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Table 8. CTV to PTV margin estimation from systematic and random tumour 
variation and set-up errors 
 
 
x direction  y direction  z direction 
 Σ 
(mm)  
σ 
(mm) 
 
Σ 
(mm)  
σ 
(mm) 
 
Σ 
(mm)  
σ 
(mm) 
Periodic 
motion 1.0  1.0 
 0.3  0.3  0.7  0.7 
Baseline 
variation 1.5  1.7 
 2.8  3.0  2.0  2.3 
Set-up error 1.5  2.4  1.9  2.9  1.9  2.2 
Total                5.9  2.2  8.5  2.9  7.1  2.3 
Margin CTV 
to PTV  8.1  
 
 11.4    9.4  
 
Table key: x = right-left; y = superior-inferior; z = anterior-posterior; Σ = 
systematic movement; σ = random movement; CTV = clinical target volume; 
PTV = planning target volume 
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Table 9. OAR to PRV margin estimation in the x direction from interfraction 
oesophageal variations and set-up errors 
 
 
x right lateral  x left lateral 
 
Σ (mm)  σ (mm) 
 
Σ (mm)  σ (mm) 
Periodic 
motion 0  0 
 0  0 
Baseline 
variation 1.3  2.1 
 3.6  2.7 
Set-up error 1.5  2.4  1.5  2.4 
Total                2.6  1.6  5.1  1.8 
Margin CTV 
to PTV  4.2  
 
 6.9  
 
Table key: x = right-left; Σ = systematic movement; σ = random movement; 
CTV = clinical target volume; PTV = planning target volume 
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Table 10. OAR to PRV margin estimation in the z direction from interfraction 
oesophageal variations and set-up errors 
 
 
z anterior  z posterior 
 
Σ (mm)  σ (mm) 
 
Σ (mm)  σ (mm) 
Periodic 
motion 0  0 
 0  0 
Baseline 
variation 1.8  1.8 
 1.3  2.0 
Set-up error 1.9  2.2  1.9  2.2 
Total                3.4  1.4  3.0  1.5 
Margin CTV 
to PTV  4.8  
 
 4.5  
 
Table key: z = anterior-posterior; Σ = systematic movement; σ = random 
movement; CTV = clinical target volume; PTV = planning target volume 
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Table 11. The effect of target volume changes with ABC on physical lung 
parameters 
 
Parameter Standard PTV FB PTV  ABC PTV  
  mean (SD)  mean (SD)  mean (SD) 
 
MLD (Gy) 10 (3)   12 (4)    9   (3) 
 
V20 (%) 16 (6)   19 (6)   15 (5) 
 
V13 (%) 24 (8)   27 (9.)   22 (7)   
   
   
Table key: PTV = planning target volume; FB = free-breathing; ABC = active 
breathing control; SD = + 1 SD 
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